Join us for an in-depth webinar exploring how CETSA® Selectivity Profiling empowers smarter decision-making in drug discovery.
Drew Nager will share how Pfizer Oncology leverages Pelago Bioscience’s CETSA Selectivity service to accelerate project progression, while Laurence Arnold from Pelago Bioscience will present case studies demonstrating the impact of the service across diverse targets, modalities, and stages of discovery.
The service offers an unbiased, proteome-wide view of compound interactions accessing biologically relevant targets that conventional selectivity panels often miss.
Powered by automated sample preparation and high-throughput LC/MS proteomics, the service enables analysis of approximately 100 samples/day with quantification of >5,000 proteins in lysate. As a result, you obtain actionable insights within 10 working days, accelerating the DMTA cycle and supporting data-driven lead optimization.
